Effect of argatroban on the activated partial thromboplastin time: A comparison of 21 commercial reagents

Blood Coagulation and Fibrinolysis

Volumn 16, Issue 4, 2005, Pages 251-257

  Francis, John L ^a   Hursting, Marcie J ^b  

^a FLORIDA HOSPITAL   (United States)

^b Clinical Science Consulting   (United States)

Author keywords

Activated partial thromboplastin time; Antagonists and inhibitors; Anticoagulation; Argatroban; Heparin induced thrombocytopenia; Reagents; Thrombin

Indexed keywords

ARGATROBAN; REAGENT; THROMBIN INHIBITOR;

ANTICOAGULATION; ARTICLE; DRUG EFFECT; HEPARIN INDUCED THROMBOCYTOPENIA; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL;

EID: 18944399168     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000169217.15926.d0     Document Type: Article

References (23)

1. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 118:104-109.
2. Kitchen S, Preston FE. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost 1996; 75:734-739.
3. Manzato F, Mengoni A, Grilenzoni A, Lippi G. Evaluation of the activated partial thromboplastin time (aPTT) sensitivity to heparin using five commercial reagents: implications for therapeutic monitoring. Clin Chem Lab Med 1998; 36:975-980.
4. Tripodi A, Chantarangkul V, Arbini AA, Moia M, Mannucci PM. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb Haemost 1993; 70:286-288.
5. Monreal M, Monreal L, Ruiz de Gopequi R, Espada Y, Angles AM, Monasterio J. Effects of two different doses of hirudin on aPTT, determined with eight different reagents. Thromb Haemost 1995; 73:219-222.
6. Greinacher A, Recombinant hirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A (editors); Heparin-induced thrombocytopenia, 2nd edition. New York: Marcel Dekker; 2001, pp. 349-380.
7. Greinacher A, Völpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99:73-80.
8. Greinacher A, Janssens U, Berg G, Böck M, Kwasny H, Kemkes-Matthes B, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999; 100:587-593.
9. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103:1838-1843.
10. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163:1849-1856.
11. LaMonte MP, Nash ML, Wang DZ, Woolfenden AR, Schultz J, Hursting MJ, et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke 2004; 35:1677-1682.
12. Jang I-K, Brown DFM, Giugliao RP, Anderson HV, Losordo D, Nicolau JC, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with Novastan and TPA (MINT) trial. J Am Coll Cardiol 1999; 33:1879-1885.
13. Vermeer F, Vahanian A, Fels PW, Besse P, Muller E, Van de Werf F, et al. Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI study. J Thromb Thrombolysis 2000; 10:233-240.
14. Swan SK, St Peter JV, Lambrecht LJ, Hursting MJ. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000; 20:756-770.
15. Lewis BE, Matthai WH, Cohen M, Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cathet Cardiovasc Intervent 2002; 57:177-184.
16. Jang I-K, Lewis BE, Matthai WH, Kleiman NS. Combination of a direct thrombin inhibitor, argatroban, and glycoprotein IIb/IIIa inhibitor is effective and safe in patients undergoing percutaneous coronary intervention [Abstract]. J Am Coll Cardiol 2003; 91(suppl):68A.
17. Hursting MJ, Alford K, Becker JCP, Brooks RL, Joffrion JL, Knappenberger GD, et al. Novastan (brand of argatroban); a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997; 23:503-516.
18. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20:318-329.
19. Matsuo T, Kario K, Matsuda S, Yamaguchi N, Kakishita E. Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: a multicenter clinical trial of argatroban. J Thromb Thrombolysis 1995; 2:131-136.
20. Murray P, Reddy B, Grossman E, Hammes M, Trevino S, Ferrell J, et al. Safety and tolerability of argatroban anticoagulation in patients with end-stage renal disease undergoing hemodialysis: a prospective study [Abstract]. J Thromb Haemost 2003; 1(suppl 1):P1911.
21. Tran JQ, DiCicco RA, Sheth SB, Tucci M, Pend L, Jorkasky DK, et al. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol 1999; 38:513-519.
22. Verme-Gibboney CN, Hursting MJ. Argatroban dosing in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2003; 37:970-975.
23. Antman EM, for the TIMI 9A investigators. Hirudin in acute myocardial infarction, safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994; 80:1624-1630.